Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SC vs IV Rituximab + CHOP in DLBCL
NCT04660799Phase 2Completed
- Sponsor
- Roche
- Start
- Feb 2021
- Primary completion
- May 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab in diffuse large B-cell lymphoma (DLBCL), sponsored by Roche. Started Feb 2021; status: completed.
02
Drugs
rituximab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT04660799.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04660799.